Aragen extends partnership with NeoVac for lipid product

Aragen Life Sciences Private Limited announced that it has entered into an agreement with UK-based firm, NeoVac, for manufacturing a lipid product that will support the development of lipid nanoparticles (LNP) for use in developing RNA vaccines for various diseases. Aragen has been working with NeoVac since early December 2021 on process research development (PRD) for the lipid product. NeoVac is creating revolutionary and proprietary next generation LNP to enable better RNA vaccines for various diseases. The LNPs are being developed using cutting-edge technology that makes RNA vaccines more thermostable and accessible with broader capabilities and fewer side effects.

Announcing the collaboration, Dr Ramesh Subramanian, Chief Commercial Officer, Aragen, said, “We are delighted to see the extension of our collaboration with NeoVac into manufacturing. Having been associated with the project at the development phase will enable a seamless transition to the manufacturing phase.” Eran Eilat, CEO, NeoVac, added “NeoVac is working on multiple RNA vaccine projects that aim to bring the next generation of this technology to millions around the world with outstanding unique qualities. Our partnership with Aragen during the development phase has been fruitful and we are happy to extend the collaboration into the manufacturing phase.”